非酒精性脂肪性肝病：内脏脂肪组织的作用
Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue.
作者信息
Hanlon Courtney L, Yuan Liyun
机构信息
Department of Medicine University of Southern California Keck School of Medicine of USC Los Angeles CA.
Division of Gastrointestinal and Liver Diseases University of Southern California Keck Hospital of USC Los Angeles CA.
出版信息
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):106-110. doi: 10.1002/cld.1183. eCollection 2022 Mar.
Abstract
Content available: Author Audio Recording.
摘要
内容提供
作者音频记录。
相似文献
1
Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue.非酒精性脂肪性肝病：内脏脂肪组织的作用
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):106-110. doi: 10.1002/cld.1183. eCollection 2022 Mar.
2
Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.低脂联素血症在2型糖尿病患者非酒精性脂肪性肝病的发生发展中起关键作用，且独立于内脏脂肪组织。
Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21. doi: 10.1111/j.1530-0277.2006.00281.x.
3
Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.非肥胖非酒精性脂肪性肝病中非酒精性肝炎和显著纤维化的预测因素。
Liver Int. 2019 Feb;39(2):332-341. doi: 10.1111/liv.13983. Epub 2018 Oct 27.
4
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中的内脏脂肪组织内脏素。
Ann Hepatol. 2010 Jul-Sep;9(3):266-70.
5
The Shift from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的转变
Clin Liver Dis (Hoboken). 2022 Nov 25;20(5):157-161. doi: 10.1002/cld.1250. eCollection 2022 Nov.
6
Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic fatty liver disease.内脏脂肪组织面积作为非酒精性脂肪性肝病中肝酶升高的独立危险因素。
Medicine (Baltimore). 2015 Mar;94(9):e573. doi: 10.1097/MD.0000000000000573.
7
Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents.肥胖青少年非酒精性脂肪性肝病患病率与内脏脂肪的关系。
Dig Liver Dis. 2008 Feb;40(2):132-9. doi: 10.1016/j.dld.2007.09.009. Epub 2007 Dec 21.
8
Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease.内脏脂肪堆积和胰岛素抵抗是非酒精性脂肪性肝病的重要因素。
J Gastroenterol. 2006 May;41(5):462-9. doi: 10.1007/s00535-006-1790-5.
9
Improvement in nonalcoholic fatty liver disease through bariatric surgery.通过减肥手术改善非酒精性脂肪性肝病
Clin Liver Dis (Hoboken). 2022 Jul 22;20(1):13-17. doi: 10.1002/cld.1229. eCollection 2022 Jul.
10
Duodenal mucosal resurfacing for nonalcoholic fatty liver disease.十二指肠黏膜重建治疗非酒精性脂肪性肝病
Clin Liver Dis (Hoboken). 2022 Nov 25;20(5):166-169. doi: 10.1002/cld.1255. eCollection 2022 Nov.
引用本文的文献
1
Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴一家三级医院对2型糖尿病患者的非酒精性脂肪性肝病评估。
J Diabetes Res. 2025 Aug 23;2025:5555842. doi: 10.1155/jdr/5555842. eCollection 2025.
2
Prolonged Water-Only Fasting Followed by a Whole-Plant-Food Diet Promotes Fat-Free Mass Recovery and Continued Fat Mass Loss in Adults With Overweight or Obesity.长期仅饮水禁食后采用全植物性食物饮食可促进超重或肥胖成年人瘦体重恢复并持续减少脂肪量。
Obes Sci Pract. 2025 Aug 5;11(4):e70086. doi: 10.1002/osp4.70086. eCollection 2025 Aug.
3
In-vivo liver proton density fat fraction quantification at 0.55 T: a pilot study with comparison against 3 T MRI.0.55T下肝脏质子密度脂肪分数的活体定量：一项与3T MRI对比的初步研究。
MAGMA. 2025 Jul 15. doi: 10.1007/s10334-025-01277-9.
4
Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.瘦素状态对非酒精性脂肪性肝病（NAFLD）患者死亡率的影响：一项系统评价和荟萃分析。
Pak J Med Sci. 2025 Jun;41(6):1845-1853. doi: 10.12669/pjms.41.6.12044.
5
The interplay between white adipose tissue, adipokines, and structural gray matter changes.白色脂肪组织、脂肪因子与脑灰质结构变化之间的相互作用。
Hum Brain Mapp. 2024 Jun 15;45(9):e26752. doi: 10.1002/hbm.26752.
6
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.噻唑烷二酮与钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者代谢功能障碍相关脂肪性肝病的协同益处：一项为期24周的开放标签随机对照试验
BMC Med. 2025 May 7;23(1):266. doi: 10.1186/s12916-025-04017-x.
7
The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model.表达醛铁蛋白的大肠杆菌Nissle 1917联合饮食改变对代谢相关脂肪性肝病小鼠模型内脏脂肪组织的影响。
Int J Obes (Lond). 2025 Apr 10. doi: 10.1038/s41366-025-01774-w.
8
Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.探寻非酒精性脂肪性肝病/非酒精性脂肪性肝炎与心脏代谢综合征之间的联系
Eur Cardiol. 2024 May 9;19:e03. doi: 10.15420/ecr.2023.26. eCollection 2024.
9
Hypercaloric low-carbohydrate high-fat diet protects against the development of nonalcoholic fatty liver disease in obese mice in contrast to isocaloric Western diet.与等热量的西方饮食相比，高热量低碳水化合物高脂肪饮食可预防肥胖小鼠非酒精性脂肪性肝病的发生。
Front Nutr. 2024 Mar 20;11:1366883. doi: 10.3389/fnut.2024.1366883. eCollection 2024.
10
White adipose tissue distribution and amount are associated with increased white matter connectivity.白色脂肪组织的分布和数量与增加的白质连通性有关。
Hum Brain Mapp. 2024 Apr;45(5):e26654. doi: 10.1002/hbm.26654.
本文引用的文献
1
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.腰围作为临床实践中的生命体征：IAS 和 ICCR 内脏肥胖工作组的共识声明。
Nat Rev Endocrinol. 2020 Mar;16(3):177-189. doi: 10.1038/s41574-019-0310-7. Epub 2020 Feb 4.
2
Adiponectin and leptin in the diagnosis and therapy of NAFLD.脂联素和瘦素在非酒精性脂肪性肝病诊断与治疗中的作用
Metabolism. 2020 Feb;103:154028. doi: 10.1016/j.metabol.2019.154028. Epub 2019 Nov 27.
3
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.内脏和异位脂肪、动脉粥样硬化和代谢性心血管疾病：立场声明。
Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725. doi: 10.1016/S2213-8587(19)30084-1. Epub 2019 Jul 10.
4
Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes.内脏脂肪指数（VAI）、脂堆积产物（LAP）和甘油三酯与葡萄糖的乘积（TyG）用于鉴别糖尿病前期和糖尿病。
Sci Rep. 2019 Jul 4;9(1):9693. doi: 10.1038/s41598-019-46187-8.
5
Body Composition Profiling in the UK Biobank Imaging Study.英国生物库影像研究中的身体成分分析。
Obesity (Silver Spring). 2018 Nov;26(11):1785-1795. doi: 10.1002/oby.22210. Epub 2018 May 22.
6
Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management.肥胖的心血管和代谢异质性：临床挑战及管理意义。
Circulation. 2018 Mar 27;137(13):1391-1406. doi: 10.1161/CIRCULATIONAHA.117.029617.
7
Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.依帕列净减少非肥胖型2型糖尿病合并内脏肥胖患者的心外膜脂肪堆积：一项初步研究。
Diabetes Ther. 2017 Aug;8(4):851-861. doi: 10.1007/s13300-017-0279-y. Epub 2017 Jun 14.
8
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.噻唑烷二酮类药物与非酒精性脂肪性肝炎中的晚期肝纤维化：一项荟萃分析。
JAMA Intern Med. 2017 May 1;177(5):633-640. doi: 10.1001/jamainternmed.2016.9607.
9
Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.脂联素作为噻唑烷二酮类药物治疗非酒精性脂肪性肝炎的靶点：一项系统评价。
Metabolism. 2016 Sep;65(9):1297-306. doi: 10.1016/j.metabol.2016.05.013. Epub 2016 May 27.
10
Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study).测量体重指数和腰围对评估内脏脂肪增多及相关心脏代谢风险谱的有用性（来自INSPIRE ME IAA研究）
Am J Cardiol. 2015 Feb 1;115(3):307-15. doi: 10.1016/j.amjcard.2014.10.039. Epub 2014 Nov 13.
Zotero 插件